BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A
Ping Guo1, Shijia Zu2, Shilong Han1
1Institute of Cancer Stem Cells, Dalian Medical University, Dalian, 116044, China.
Abstract:
As the largest subunit of the nuclear remodeling factor complex, Bromodomain PHD Finger Transcription Factor (BPTF) has been reported to be involved in tumorigenesis and development in several cancers. However, to date, its functions and related molecular mechanisms in colorectal cancer (CRC) are still poorly defined and deserve to be revealed. In this study, we uncovered that, under the expression regulation of c-Myc, BPTF promoted CRC progression by targeting Cdc25A. BPTF was found to be highly expressed in CRC and promoted the proliferation and metastasis of CRC cells through BPTF specific siRNAs, shRNAs or inhibitors. Based on RNA-seq, combined with DNA-pulldown, ChIP and luciferase reporter assay, we proved that, by binding to -178/+107 region within Cdc25A promoter, BPTF transcriptionally activated Cdc25A, thus accelerating the cell cycle process of CRC cells. Meanwhile, BPTF itself was found to be transcriptionally regulated by c-Myc. Moreover, BPTF knockdown or inactivation was verified to sensitize CRC cells to chemotherapeutics, 5-Fluorouracil (5FU) and Oxaliplatin (Oxa), c-Myc inhibitor and cell cycle inhibitor not just at the cellular level in vitro, but in subcutaneous xenografts or AOM/DSS-induced in situ models of CRC in mice, while Cdc25A overexpression partially reversed BPTF silencing-caused tumor growth inhibition. Clinically, BPTF, c-Myc and Cdc25A were highly expressed in CRC tissues simultaneously, the expression of any two of the three was positively correlated, and their expressions were highly relevant to tumor differentiation, TNM staging and poor prognosis of CRC patients. Thus, our study indicated that the targeted inhibition of BPTF alone, or together with chemotherapy and/or cell cycle-targeted therapy, might act as a promising new strategy for CRC treatment, while c-Myc/BPTF/Cdc25A signaling axis is expected to be developed as an associated set of candidate biomarkers for CRC diagnosis and prognosis prediction.
Insights
Bromodomain PHD Finger Transcription Factor (BPTF) drives colorectal cancer (CRC) growth by activating Cdc25A, regulated by c-Myc. Inhibiting BPTF shows promise for CRC treatment and prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Bromodomain PHD Finger Transcription Factor (BPTF) is implicated in various cancers.
- The specific role and mechanisms of BPTF in colorectal cancer (CRC) remain largely undefined.
- Understanding BPTF's function is crucial for developing novel CRC therapeutic strategies.
Purpose of the Study:
- To elucidate the function and molecular mechanisms of BPTF in colorectal cancer (CRC) progression.
- To investigate the regulatory relationship between BPTF, c-Myc, and Cdc25A in CRC.
- To evaluate the therapeutic potential of targeting BPTF in CRC treatment.
Main Methods:
- Utilized BPTF-specific siRNAs, shRNAs, and inhibitors to assess proliferation and metastasis.
- Employed RNA-sequencing, DNA-pulldown, ChIP, and luciferase reporter assays to determine molecular interactions.
- Validated findings in vitro, in mouse xenograft models, and in AOM/DSS-induced CRC models.
Main Results:
- BPTF is highly expressed in CRC and promotes proliferation and metastasis by transcriptionally activating Cdc25A.
- BPTF expression is regulated by c-Myc, forming a c-Myc/BPTF/Cdc25A signaling axis.
- BPTF inhibition sensitizes CRC cells to chemotherapy (5-FU, Oxaliplatin) and delays tumor growth in vivo.
- Simultaneous high expression of BPTF, c-Myc, and Cdc25A correlates with poor prognosis in CRC patients.
Conclusions:
- The c-Myc/BPTF/Cdc25A axis drives CRC progression and is a potential therapeutic target.
- Targeting BPTF, alone or in combination with chemotherapy, offers a promising strategy for CRC treatment.
- The c-Myc/BPTF/Cdc25A signaling pathway serves as a valuable biomarker for CRC diagnosis and prognosis.
Related Concept Videos
Abnormal Proliferation
Inhibition of Cdk Activity
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...


